Drug Profile
Catumaxomab - Neovii Biotech
Alternative Names: Anti-CD3 anti-EpCAM monoclonal antibody; Anti-EpCAM anti-CD3 monoclonal antibody; LP-000; RemovabLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Lindis Biotech; TRION Pharma
- Developer Lindis Biotech; Linton Pharm; Neovii Biotech; Swedish Orphan Biovitrum; TRION Pharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Gastric cancer; Malignant ascites
- Phase I/II Bladder cancer
- No development reported Colorectal cancer
- Discontinued Carcinoma; Ovarian cancer
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for clinical-Phase-Unknown development in Bladder-cancer in China (Parenteral)
- 28 Nov 2023 No recent reports of development identified for clinical-Phase-Unknown development in Colorectal-cancer(Recurrent) in China (Parenteral)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Bladder-cancer(Recurrent, Second-line therapy or greater) in Germany (Intravesicular)